No Racial Disparities Seen in Long-Term MACE for Women With CAD
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 30, 2023 -- For women with obstructive coronary artery disease (CAD), there are no racial and ethnic disparities in long-term major adverse cardiovascular events (MACE) or cardiovascular mortality, according to a research letter published online Oct. 25 in the Canadian Journal of Cardiology.
Judy M. Luu, M.D., Ph.D., from McGill University Health Centre in Montreal, and colleagues evaluated long-term adverse outcomes for Black and non-Black women with obstructive CAD from the Women's Ischemia Syndrome Evaluation cohort.
Overall, 38 percent of the 944 women (17 percent non-Hispanic Black) had obstructive CAD. The researchers found that among participants with CAD, Black women had significantly higher body mass index, more hypertension, and higher rates of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use when compared with non-Black women. The primary outcome for the composite of MACE included all-cause mortality, nonfatal myocardial infarction, stroke, and hospitalization for angina or heart failure and occurred in 68 and 58.6 percent of Black and non-Black women with CAD, respectively. For women with CAD, the risk for MACE did not differ significantly for Black versus non-Black women; these findings persisted when adjusting for age and cardiovascular risk factors. Being Black was also associated with a similar risk for cardiovascular mortality.
"Despite Black women having a greater burden of cardiovascular risk factors and lower socioeconomic position compared with non-Black women, long-term cardiovascular disease outcomes were similar," the authors write.
Two authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older
TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.